Mirvetuximab soravtansine

FDA-approved

Elahere; IMGN853

Target

Folate receptor alpha · FOLR1

Sponsor

ImmunoGen/AbbVie

Indication

FOLR1+ ovarian cancer

Target family

GPI-anchored

RP2D dose

6 mg/kg AIBW

Q3WRP2D

Multi-organ toxicity

Fingerprint & organ drill-down

Also reported

0%severity100%

Assessed · clear

true 0%

No data

never assessed

130 adverse-event terms

Ocular

Any-grade

59%

G3+

11%

RP2D

sagittal schematic · Reversible

↳

Tissues shaded by reported adverse-event rate.

Cornea

36%

Express.

0.02%

Limbus

Express.

0.07%

Conjunctiva

Express.

0.19%

Lens

Express.

Retina / RPE

Express.

3.21%

0.4 nTPM

Off-target signature

36% corneal toxicity, yet the Folate receptor alpha target is detected in only 0.02% of central cornea - toxicity is not explained by target expression.

Dominant tissue

Cornea

Surface subtype

Corneal (off-target)

Reversibility

Reversible

Reported ocular events

Ocular adverse reactions59%

G3+ 11.3%n=682

Vision blurred50%

G3+ 7%n=106

VISION BLURRED44.49%

non-seriousn=227

Blurred vision44.44%

non-seriousn=18

Vision Blurred44.19%

non-seriousn=86

Keratopathy37%

G3+ 9%n=106

CATARACT34.18%

non-seriousn=79

DRY EYE32.16%

non-seriousn=227

Dry eye27%

G3+ 2%n=106

Punctate keratitis25%

non-seriousn=243

PHOTOPHOBIA16.46%

non-seriousn=79

Cataract16%

G3+ 3%n=682

Photophobia14%

G3+ 0.5%n=682

Corneal disorder10.71%

non-seriousn=28

Eye pain10%

n=243

VISUAL ACUITY REDUCED8.86%

non-seriousn=79

VITREOUS FLOATERS7.49%

non-seriousn=227

Visual acuity reduced6.98%

non-seriousn=86

Visual impairment6.98%

non-seriousn=86

Vitreous floaters6.98%

non-seriousn=86

Eye Pain6.98%

non-seriousn=86

EYE PAIN6.33%

non-seriousn=79

CORNEAL EPITHELIAL MICROCYSTS6.33%

non-seriousn=79

Corneal ulcer5.56%

seriousn=18

Eye disorders - Other, specify5.56%

non-seriousn=18

Foreign body sensation in eyes3.7%

non-seriousn=243

Keratitis3.29%

non-seriousn=243

Eye irritation2.88%

non-seriousn=243

Lacrimation increased2.47%

non-seriousn=243

Conjunctivitis2.06%

non-seriousn=243

Corneal deposits2.06%

non-seriousn=243

Eye pruritus2.06%

non-seriousn=243

Ocular discomfort2.06%

non-seriousn=243

Intraocular pressure increased1.65%

non-seriousn=243

Blepharitis1.23%

non-seriousn=243

Diplopia1.23%

non-seriousn=243

Glaucoma1.23%

non-seriousn=243

Photopsia1.23%

non-seriousn=243

Uveitis1%

n=243

Retinal haemorrhage0.97%

non-seriousn=206

Vitreous degeneration0.97%

non-seriousn=206

Asthenopia0.82%

non-seriousn=243

Chalazion0.82%

non-seriousn=243

Conjunctival haemorrhage0.82%

non-seriousn=243

Lacrimation decreased0.82%

non-seriousn=243

Ocular hyperaemia0.82%

non-seriousn=243

Conjunctival hyperaemia0.82%

non-seriousn=243

Metamorphopsia0.82%

non-seriousn=243

Xerophthalmia0.82%

non-seriousn=243

Corneal epithelial microcysts0.76%

non-seriousn=264

Blepharospasm0.76%

non-seriousn=264

Corneal epithelium defect0.76%

non-seriousn=264

Eye discharge0.76%

non-seriousn=264

Optic disc drusen0.76%

non-seriousn=264

Corneal dystrophy0.49%

non-seriousn=206

Corneal erosion0.49%

non-seriousn=206

Corneal lesion0.49%

non-seriousn=206

Corneal opacity0.49%

seriousn=206

Corneal pigmentation0.49%

non-seriousn=206

Eye infection bacterial0.49%

non-seriousn=206

Eye infection fungal0.49%

non-seriousn=206

Iritis0.49%

non-seriousn=206

Lagophthalmos0.49%

non-seriousn=206

Limbal stem cell deficiency0.49%

non-seriousn=206

Macular degeneration0.49%

non-seriousn=206

Macular fibrosis0.49%

non-seriousn=206

Retinal vein occlusion0.49%

non-seriousn=206

Vitreous adhesions0.49%

non-seriousn=206

KERATITIS0.44%

seriousn=227

KERATOPATHY0.44%

seriousn=227

RETINAL DETACHMENT0.44%

seriousn=227

Abnormal sensation in eye0.41%

non-seriousn=243

Corneal abrasion0.41%

non-seriousn=243

Corneal cyst0.41%

non-seriousn=243

Corneal oedema0.41%

non-seriousn=243

Eye disorder0.41%

non-seriousn=243

Retinopathy0.41%

non-seriousn=243

Vitreous detachment0.41%

non-seriousn=243

Eye swelling0.41%

non-seriousn=243

Meibomianitis0.41%

non-seriousn=243

Myopia0.41%

non-seriousn=243

Pterygium0.41%

non-seriousn=243

Retinal drusen0.41%

non-seriousn=243

Trichiasis0.41%

non-seriousn=243

Keratitis bacterial0.41%

non-seriousn=243

Ocular hypertension0.41%

non-seriousn=243

Acquired corneal dystrophy0.41%

non-seriousn=243

Retinal detachment0.41%

non-seriousn=243

Age-related macular degeneration0.41%

non-seriousn=243

Blepharochalasis0.41%

non-seriousn=243

Cataract nuclear0.41%

non-seriousn=243

Conjunctival irritation0.41%

non-seriousn=243

Dyschromatopsia0.41%

non-seriousn=243

Eye inflammation0.41%

non-seriousn=243

Eyelid oedema0.41%

non-seriousn=243

Eyelid pain0.41%

non-seriousn=243

Eyelid skin dryness0.41%

non-seriousn=243

Halo vision0.41%

non-seriousn=243

Hypermetropia0.41%

non-seriousn=243

Night blindness0.41%

non-seriousn=243

Ocular toxicity0.41%

non-seriousn=243

Optic nerve disorder0.41%

non-seriousn=243

Papilloedema0.41%

non-seriousn=243

Periorbital oedema0.41%

non-seriousn=243

Pupils unequal0.41%

non-seriousn=243

Superficial injury of eye0.41%

non-seriousn=243

Sympathetic ophthalmia0.41%

non-seriousn=243

Eye contusion0.38%

non-seriousn=264

Eye infection0.38%

non-seriousn=264

Posterior capsule opacification0.38%

non-seriousn=264

Angle closure glaucoma0.38%

non-seriousn=264

Aphakia0.38%

non-seriousn=264

Astigmatism0.38%

non-seriousn=264

Blindness transient0.38%

non-seriousn=264

Cataract operation complication0.38%

non-seriousn=264

Conjunctivitis viral0.38%

non-seriousn=264

Corneal infection0.38%

non-seriousn=264

Corneal toxicity0.38%

non-seriousn=264

Eye allergy0.38%

non-seriousn=264

Eye haemorrhage0.38%

non-seriousn=264

Glare0.38%

non-seriousn=264

Intraocular lens implant0.38%

non-seriousn=264

Keratitis viral0.38%

non-seriousn=264

Lenticular opacities0.38%

non-seriousn=264

Maculopathy0.38%

non-seriousn=264

Optic atrophy0.38%

non-seriousn=264

Orbital oedema0.38%

non-seriousn=264

Pinguecula0.38%

non-seriousn=264

Vitreous opacities0.38%

non-seriousn=264

Meibomian gland dysfunction0.38%

non-seriousn=264

Per-trial detail

Adverse events by trial

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin,PHASE1|PHASE2real-worldn=264CTCAE NR (ClinicalTrials.govPooledC

ClinicalTrials.gov NCT02606305 posted results, adverse events module (serious; 1/264 pooled across arms)

632 adverse-event terms · 22 systems · expand a system below

GI88

Constipation

29.17%non-serious

77/264

Abdominal distension

21.97%non-serious

58/264

Abdominal pain upper

12.88%non-serious

34/264

Dyspepsia

10.98%non-serious

29/264

Stomatitis

10.98%non-serious

29/264

Dry mouth

10.61%non-serious

28/264

Gastrooesophageal reflux disease

7.95%non-serious

21/264

Small intestinal obstruction

7.2%serious

19/264

Abdominal discomfort

3.79%non-serious

10/264

Diarrhoea

3.41%serious

9/264

Flatulence

3.03%non-serious

8/264

Gingival bleeding

3.03%non-serious

8/264

Abdominal pain lower

2.65%non-serious

7/264

Haemorrhoids

2.65%non-serious

7/264

Dysphagia

2.27%non-serious

6/264

Faeces soft

2.27%non-serious

6/264

Vomiting

2.27%serious

6/264

Gingival pain

1.89%non-serious

5/264

Haematochezia

1.89%non-serious

5/264

Haemorrhoidal haemorrhage

1.89%non-serious

5/264

Colitis

1.52%serious

4/264

Dental caries

1.52%non-serious

4/264

Frequent bowel movements

1.52%non-serious

4/264

Gastrointestinal haemorrhage

1.52%serious

4/264

Nausea

1.52%serious

4/264

Anal incontinence

1.14%non-serious

3/264

Hyperaesthesia teeth

1.14%non-serious

3/264

Toothache

1.14%non-serious

3/264

Abdominal pain

0.76%serious

2/264

Abdominal tenderness

0.76%non-serious

2/264

Anorectal discomfort

0.76%non-serious

2/264

Glossodynia

0.76%non-serious

2/264

Intestinal obstruction

0.76%non-serious

2/264

Large intestinal obstruction

0.76%serious

2/264

Large intestine perforation

0.76%serious

2/264

Mouth haemorrhage

0.76%non-serious

2/264

Mouth ulceration

0.76%non-serious

2/264

Noninfective gingivitis

0.76%non-serious

2/264

Oral pain

0.76%non-serious

2/264

Proctalgia

0.76%non-serious

2/264

Rectal haemorrhage

0.76%serious

2/264

Retching

0.76%non-serious

2/264

Abdominal hernia

0.38%non-serious

1/264

Anal fissure

0.38%non-serious

1/264

Anal haemorrhage

0.38%non-serious

1/264

Aphthous ulcer

0.38%non-serious

1/264

Ascites

0.38%serious

1/264

Colonic fistula

0.38%serious

1/264

Defaecation urgency

0.38%non-serious

1/264

Duodenal ulcer haemorrhage

0.38%serious

1/264

Duodenal ulcer perforation

0.38%non-serious

1/264

Dyschezia

0.38%non-serious

1/264

Enteritis

0.38%serious

1/264

Enterocolitis

0.38%non-serious

1/264

Epigastric discomfort

0.38%non-serious

1/264

Faeces discoloured

0.38%non-serious

1/264

Faeces hard

0.38%non-serious

1/264

Gastric ulcer

0.38%non-serious

1/264

Gastric varices

0.38%serious

1/264

Gastritis

0.38%non-serious

1/264

Gastrointestinal angiectasia

0.38%non-serious

1/264

Gastrointestinal mucosa hyperaemia

0.38%non-serious

1/264

Gingival recession

0.38%non-serious

1/264

Haematemesis

0.38%serious

1/264

Hiatus hernia

0.38%non-serious

1/264

Hypoaesthesia oral

0.38%non-serious

1/264

Intestinal perforation

0.38%serious

1/264

Large intestinal ulcer

0.38%non-serious

1/264

Lip dry

0.38%non-serious

1/264

Lip pain

0.38%non-serious

1/264

Malignant gastrointestinal obstruction

0.38%serious

1/264

Melaena

0.38%non-serious

1/264

Odynophagia

0.38%non-serious

1/264

Oesophageal haemorrhage

0.38%serious

1/264

Oesophageal pain

0.38%non-serious

1/264

Oesophagitis

0.38%non-serious

1/264

Oral mucosal hypertrophy

0.38%non-serious

1/264

Pancreatitis

0.38%serious

1/264

Rectal discharge

0.38%non-serious

1/264

Rectal fissure

0.38%non-serious

1/264

Salivary duct inflammation

0.38%non-serious

1/264

Small intestinal perforation

0.38%serious

1/264

Teeth brittle

0.38%non-serious

1/264

Tongue discolouration

0.38%non-serious

1/264

Tongue ulceration

0.38%non-serious

1/264

Tooth loss

0.38%non-serious

1/264

Umbilical hernia

0.38%non-serious

1/264

Varices oesophageal

0.38%non-serious

1/264

Infections70

Ocular65

Vision blurred

56.82%non-serious

150/264

Dry eye

32.2%non-serious

85/264

Keratopathy

26.14%non-serious

69/264

Cataract

18.18%non-serious

48/264

Eye pain

11.36%non-serious

30/264

Visual acuity reduced

10.98%non-serious

29/264

Photophobia

9.09%non-serious

24/264

Corneal cyst

6.06%non-serious

16/264

Keratitis

4.17%non-serious

11/264

Vitreous floaters

4.17%non-serious

11/264

Eye irritation

3.79%non-serious

10/264

Corneal deposits

2.27%non-serious

6/264

Diplopia

2.27%non-serious

6/264

Eye pruritus

2.27%non-serious

6/264

Visual impairment

1.89%non-serious

5/264

Foreign body sensation in eyes

1.52%non-serious

4/264

Lacrimation increased

1.52%non-serious

4/264

Blepharitis

1.14%non-serious

3/264

Glaucoma

1.14%non-serious

3/264

Intraocular pressure increased

1.14%non-serious

3/264

Blepharospasm

0.76%non-serious

2/264

Conjunctival haemorrhage

0.76%non-serious

2/264

Conjunctivitis

0.76%non-serious

2/264

Corneal abrasion

0.76%non-serious

2/264

Corneal epithelial microcysts

0.76%non-serious

2/264

Corneal epithelium defect

0.76%non-serious

2/264

Eye discharge

0.76%non-serious

2/264

Meibomianitis

0.76%non-serious

2/264

Ocular discomfort

0.76%non-serious

2/264

Ocular hyperaemia

0.76%non-serious

2/264

Optic disc drusen

0.76%non-serious

2/264

Photopsia

0.76%non-serious

2/264

Angle closure glaucoma

0.38%non-serious

1/264

Aphakia

0.38%non-serious

1/264

Astigmatism

0.38%non-serious

1/264

Blindness transient

0.38%non-serious

1/264

Cataract operation complication

0.38%non-serious

1/264

Conjunctival hyperaemia

0.38%non-serious

1/264

Conjunctivitis viral

0.38%non-serious

1/264

Corneal infection

0.38%non-serious

1/264

Corneal toxicity

0.38%non-serious

1/264

Eye allergy

0.38%non-serious

1/264

Eye contusion

0.38%non-serious

1/264

Eye haemorrhage

0.38%non-serious

1/264

Eye infection

0.38%non-serious

1/264

Eye swelling

0.38%non-serious

1/264

Glare

0.38%non-serious

1/264

Intraocular lens implant

0.38%non-serious

1/264

Keratitis viral

0.38%non-serious

1/264

Lenticular opacities

0.38%non-serious

1/264

Maculopathy

0.38%non-serious

1/264

Myopia

0.38%non-serious

1/264

Optic atrophy

0.38%non-serious

1/264

Orbital oedema

0.38%non-serious

1/264

Pinguecula

0.38%non-serious

1/264

Posterior capsule opacification

0.38%non-serious

1/264

Pterygium

0.38%non-serious

1/264

Punctate keratitis

0.38%non-serious

1/264

Retinal drusen

0.38%non-serious

1/264

Trichiasis

0.38%non-serious

1/264

Uveitis

0.38%non-serious

1/264

Vitreous detachment

0.38%non-serious

1/264

Vitreous opacities

0.38%non-serious

1/264

Acquired corneal dystrophy

0.38%non-serious

1/264

Meibomian gland dysfunction

0.38%non-serious

1/264

General50

Dermatologic49

Pulmonary42

Neurologic (other)38

Musculoskeletal34

Injury26

Investigations26

Renal22

Metabolic21

Other17

Ear14

Psychiatric13

Cardiac12

Vascular11

Hematologic10

Hepatic10

Endocrine5

Neoplasms5

Immune4

Construct

Molecular anatomy

Antibody

IgG1

Chimeric

Linker

Cleavable

3.4

DAR

Payload

DM4 (free)

Tubulin inhibitor

Linker structureC13H14N2O7S3

[H]OS(=O)(=O)C([H])(C(=O)ON1C(=O)C([H])([H])C([H])([H])C1=O)C([H])([H])C([H])([H])SSc1nc([H])c([H])c([H])c1[H]

Payload structureC38H54ClN3O10S

C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)C)\C)OC)(NC(=O)O2)O

Antibody

Antibody & Fc engineering

Antibody

M9346A

Isotype

IgG1

Origin

Chimeric

Fc modifications

None^inferred

Glycoengineering

Standard^inferred

Effector silencing

None^inferred

FcγR binding

Retained

C1q binding

Retained^inferred

Target KD (nM)

0.36^unver.

Linker & conjugation

Linker chemistry

Linker profile

Linker

SPDB / sulfo-SPDB

Class

Cleavable

Cleavage

Cleavable

Attachment

Lysine

Conjugation

Conventional Lys (NHS sulfo-SPDB)

Symmetry

Asymmetric

DAR (mean)

3.4

DAR homogeneity

Heterogeneous

Plasma t½

4.8 d

Cleavage trigger

GSH/reductive (disulfide)

Release control

Conditional

Hydrophilicity mask

Sulfonate

Cell line

Chinese Hamster Ovary

Formula

C13H14N2O7S3

Linker MW

406.463 Da

Linker TPSA

189.92 Å²

Linker xLogP

1.0756

ADCdb linker

LIN0MESCO

In-vitro stability

Stability note

Hindered disulfide; ADC t½ ~5–7 d (Pouzin 2022 mirvetuximab popPK); released DM4 undergoes S-methylation to S-Me-DM4 with formation-limited kinetics (Tu BJCP 2024 confirmed)

Payload

Payload & physicochemistry

Payload profile

Payload

DM4 (free)

Class

Maytansinoid

Mechanism

Tubulin inhibitor

Released catabolite

DM4 and S-methyl-DM4 (S-methyl-DM4 is the predominant circulating active catabolite)

Mechanistic subtype

Tubulin-maytansinoid

Stereochem / salt

Free thiol

Bystander

Yes

PAMPA rank

780.4 Da

XLogP3

3.2

logD₇.₄

TPSA

157 Å²

pKa

10.3 pKa

Charge pH 7.4

H-bond donors

H-bond acceptors

IC50 (HCEC)

Formula

C38H54ClN3O10S

PubChem CID

11686439

ADCdb payload

PAY0GTSVM

Plasma protein binding (%)

99 %

Hydrophobicity · logD₇.₄

hydrophilic −2+3+4 lipophilic

Bioactivity note

ADCdb-reported ADC potency (IC50): KB cells 0.15 +/- 0.08 nM; JEG-3 0.20 +/- 0.10 nM; IGROV-1 1.00 +/- 0.40 nM; END-2 0.20 ug/mL; END-1 74.6 ug/mL. Source: ADCdb DRG0GKOZH.

Dosing & regimen

Dosing

RP2D dose

6 mg/kg AIBW

Schedule

Q3W

Route

Fractionated

n at RP2D

682

Dose basis

Switched: TBW→AIBW

Trial phase

Approved

Dose-OAE available

Yes

Tox summary basis

RP2D

Pharmacology

Clinical pharmacokinetics

By analyte · FDA label §12.3 + Drugs@FDA clinical-pharmacology reviews

	Intact ADC	Free payload
Cmax	137.3µg/mL	4.1ng/mL
AUC	20.6h*mg/mL+1	530h*ng/mL+1
Tmax	end of infusion	~2days
t½	4.8days	2.8days
CL	19mL/hour	14L/hour
Vd	2.6L+1	—

FDA label §12.3 Drugs@FDA reviewhover a value for dose / population / source · “+N” marks additional reported values

Ocular & expression

Ocular profile & eye-tissue target expression

Target profile

OAE any-grade

59 %

OAE grade 3+

11 %

OAE data status

reported

Severity (weighted)

25.4

Keratopathy

36 %

Conjunctival

Dry eye

27 %

Blurred vision

48 %

Dominant tissue

Cornea

Surface subtype

Corneal (off-target)

Grading scale

CTCAE v5.0

Reversibility

Reversible

Target expression in eye tissues (HCA detection · HPA bulk)

Cornea (central)

0.02 %

Cornea (limbal)

0.07 %

Conjunctiva

0.19 %

RPE

3.21 %

Retina (HPA)

0.4 nTPM

Cross-trial comparability · source-verified

Ascertainment: Systematic eye examsScale: CTCAE v5Denominator: RP2D

Dose & schedule → ocular toxicity · keratopathy (any-grade) by cohort

1.1 mg/kg

Weekly

20%

n=5 · First-in-Human IMGN853

1.8 mg/kg

Weekly

25%

n=4 · First-in-Human IMGN853

2.0 mg/kg

Weekly

22.2%

n=9 · First-in-Human IMGN853

2.5 mg/kg

Weekly

14.3%

n=7 · First-in-Human IMGN853

3.3 mg/kg

IV Q3W

11.1%

n=9 · First-in-Human IMGN853

5 mg/kg

IV Q3W

33.3%

n=3 · FORWARD II

5 mg/kg

IV Q3W

25%

n=4 · FORWARD II

5 mg/kg

IV Q3W

25%

n=4 · FORWARD II

5 mg/kg

IV Q3W

25%

n=4 · FORWARD II

5 mg/kg

IV Q3W

25%

n=4 · FORWARD II

5 mg/kg

IV Q3W

20%

n=5 · FORWARD II

5.0 mg/kg

IV Q3W

5.6%

n=18 · First-in-Human IMGN853

6 mg/kg AIBW

Q3W

59%

n=682 · Pooled safety population (Studies 0416/0417/0403/0401)

6 mg/kg AIBW

IV Q3W (Day 1 of 21-day cycle)

37%

n=218 · MIRASOL (Study 0416) [label]

6 mg/kg AIBW

IV Q3W (Day 1 of 21-day cycle)

37%

n=106 · SORAYA (Study 0417) [label]

6 mg/kg AIBW

Q3W

37%

n=218 · MIRASOL (Study 0416)

6 mg/kg AIBW

Q3W

37%

n=106 · SORAYA (Study 0417)

6 mg/kg AIBW

Q3W

36%

n=682 · Pooled safety population (Studies 0416/0417/0403/0401)

6 mg/kg AIBW

IV Q3W

34.4%

n=227 · MIRASOL

6 mg/kg

IV Q3W

33.3%

n=3 · TAK-853 / mirvetuximab

6 mg/kg AIBW

IV Q3W

32.1%

n=106 · SORAYA

6 mg/kg

IV Q3W

29.4%

n=126 · FORWARD II

6.0 mg/kg

IV Q3W

14.3%

n=7 · First-in-Human IMGN853

6 mg/kg

IV Q3W

12%

n=25 · TAK-853 / mirvetuximab

6 mg/kg

IV Q3W

10%

n=10 · FORWARD II

6 mg/kg AIBW

IV Q3W

7.6%

n=79 · Mirvetuximab platinum-sensitive

6 mg/kg

IV Q3W

1.8%

n=56 · FORWARD II

6 mg/kg AIBW

IV Q3W

1.6%

n=243 · FORWARD I

6 mg/kg

n=106

7.0 mg/kg

IV Q3W

20%

n=5 · First-in-Human IMGN853

IV Q3W (Day 1 of 21-day cycle)

50%

n=2 · Mirvetuximab in TNBC

IV Q3W

48.8%

n=41 · FORWARD II

—

32.08%

n=106 · SORAYA

IV Q3W

29.2%

n=65 · Mirvetuximab + SL-172154

—

17.44%

n=86 · Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects W

IV Q3W

17.4%

n=46 · First-in-Human IMGN853

IV Q3W

11.1%

n=18 · IMGN853 + Pembrolizumab endometrial

—

10.71%

n=28 · A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Adv

—

6.33%

n=79 · PICCOLO

IV Q3W

4.2%

n=24 · First-in-Human IMGN853

IV Q3W

3.7%

n=27 · First-in-Human IMGN853

IV Q3W

2.5%

n=40 · First-in-Human IMGN853

—

2.06%

n=243 · FORWARD I

—

0.97%

n=206 · IMGN853-0401

—

0.76%

n=264 · Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin,

Per-cohort rates from the per-trial extraction, sorted by dose. Cross-trial comparison is subject to ascertainment / scale differences (see comparability above) — e.g. an early symptom-driven trial can read lower than a later systematic-exam trial at a higher dose.

Ocular AE grading reference — interspecialty consensus · 6 scales + dose modification

Identity & registry

Identifiers, registry & notes

ADC id

mirvetuximab-soravtansine

Approval status

FDA-approved

Approval year

2022

UniProt

P15328

ADCdb ADC

DRG0GKOZH

ADCdb antibody

ANI0VPFFS

ADCdb target

TAR0QHAVI

Primary source

ELAHERE PI Section 6.1; SORAYA JCO 2023; MIRASOL NEJM 2023

Aliases & development codes

Elahere; IMGN853

Notes

FOLR1 absent from cornea; OAE is DM4 bystander via cleavable disulfide. V3.1: origin corrected Humanized→Chimeric per ELAHERE label §11.